

## SUB-STUDY RETURNS

**Just in time for Lung Cancer Awareness Month, patients can enroll in a new Lung-MAP sub-study. Here's what you need to know:**

### **S1400F: Re-Opened November 2017**

This is a non-matched, Phase II study for patients whose lung cancer has progressed during or after treatment with PD-1/PD-L1 inhibitors, a new class of immunotherapy drugs. To be eligible to enroll in this sub-study, PD-1/PD-L1 inhibitors must be a patient's most recent line of treatment. S1400F is testing the combination of durvalumab and tremelimumab, drugs being developed by AstraZeneca and MedImmune. These immunotherapies are known as immune checkpoint inhibitors, which bind to cancer cells and induce an immune attack on those cells. This drug combination is also being tested in non-small cell lung cancer.

For more information on S1400F, view the protocol abstracts on [www.swog.org](http://www.swog.org) or [www.ctsu.org](http://www.ctsu.org).

### **Lung-MAP Lands in Japan**

Lung-MAP co-chair Dr. Roy Herbst of Yale Cancer Center gave a trial update at the World Conference on Lung Cancer 2017, held in Yokohama, Japan from October 14-18. Herbst reported on progress and plans:

- 740 study sites,
- 13 genetic alterations identified in patients,
- four sub-studies completed,
- two actively accruing, and two in development.

The launch of these two new sub-studies is in progress, and more are on the way. The new treatments will include armed antibodies, drug combinations, and immunotherapy combinations.



### Lung-MAP Active Study Webinar



## Lung-MAP Active Study Webinar

Get the study status and get your questions answered. Register for the webinar here: [Join WebEx Meeting](#)

Thursday, December 7, 2017  
2:00pm Eastern Standard Time  
Host: Stacey Adam  
Meeting number: 625 529 541  
Meeting password: lungmap

Audio connection:  
Call-in toll number (US/Canada)  
1-650-479-3208  
Access code: 625 529 541

**Thanks for your efforts in collecting and entering retrospective data on S1400A and S1400I! For questions, please contact [S1400question@crab.org](mailto:S1400question@crab.org)**

# STATUS REPORT

## Top Accruing Sites

Source: CTSU, As of 11/10/17

Site
1. Heartland Cancer Research NCORP
2. Southeast Clinical Oncology Research (SCOR) Consortium NCORP
3. Kaiser Permanente NCI Community Oncology Research Program
4. Roswell Park Cancer Institute LAPS
5. Georgia NCI Community Oncology Research Program
6. Duke University - Duke Cancer Institute LAPS
7. Michigan Cancer Research Consortium NCORP
8. Yale University - Yale Cancer Center LAPS
9. Indiana University - Melvin and Bren Simon Cancer Center LAPS
10. Metro Minnesota Community Oncology Research Consortium
11. Wisconsin NCI Community Oncology Research Program
12. University of Pennsylvania/Abramson Cancer Center
13. University of Texas MD Anderson Cancer Center LAPS
13. Wichita NCI Community Oncology Research Program
14. UC Davis Comprehensive Cancer Center LAPS
14. CWRU Case Comprehensive Cancer Center LAPS
15. Fred Hutchinson Cancer Research Center LAPS
15. VCU Massey Cancer Center Minority Underserved NCORP
16. University of Pittsburgh Cancer Institute LAPS
17. University of Oklahoma Health Sciences Center LAPS



# 740

Up to 740 sites have activated Lung-MAP



# 1425

Total number of patients enrolled

Source: CTSU, As of 11/17/2017

## Pre-Screening

### Don't Forget Pre-Screening

Patients with Stage IV or recurrent disease are eligible for pre-screening prior to progression on their current line of therapy. Patient benefits include:

- Free genetic tumor test
- Tumor testing nets important information about their disease
- "Plan B" if initial treatment fails

**HAVE A STORY IDEA FOR THIS NEWSLETTER?**

Contact Wendy Lawton at [lawtonw@ohsu.edu](mailto:lawtonw@ohsu.edu)

## STUDY CONTACTS GOT A LUNG-MAP QUESTION? HERE'S WHO TO CALL.

### Eligibility + Imaging + Data Submission:

Data Operations, (206) 652-2267  
[S1400Question@crab.org](mailto:S1400Question@crab.org)

### Protocol + Regulatory:

SWOG Operations Office,  
 (210) 614-8808, ext. 1019  
[cmiwa@swog.org](mailto:cmiwa@swog.org)

### Treatment + Toxicity Study Distribution Lists:

S1400: [S1400MedicalQuery@swog.org](mailto:S1400MedicalQuery@swog.org)  
 S1400F: [S1400FMedicalQuery@swog.org](mailto:S1400FMedicalQuery@swog.org)  
 S1400G: [S1400GMedicalQuery@swog.org](mailto:S1400GMedicalQuery@swog.org)  
 S1400I: [S1400IMedicalQuery@swog.org](mailto:S1400IMedicalQuery@swog.org)

### Funding Questions:

Group Chair's Office,  
[funding@swog.org](mailto:funding@swog.org)  
 For additional information,  
 see funding memos.